EAGLE GENOMICS LIMITED

Their core work

Eagle Genomics is a Cambridge-based bioinformatics SME that builds data management and analysis platforms for genomics and life sciences research. In both H2020 projects, they participated as a third party — meaning they provided infrastructure, tools, or hosted researchers rather than holding a formal consortium seat. Their contributions span immune system genomics (the molecular regulation of T helper cells) and the integration of electronic health records for clinical research. They occupy the space between raw biological data and actionable research output, functioning as a technical services partner for academic and clinical research consortia.

What they specialise in

How they've shifted over time

In their first H2020 project (2015–2019), Eagle Genomics was embedded in fundamental immunology research — specifically the genomics of T helper cell differentiation and the molecular basis of autoimmune conditions. By 2019, the focus shifted markedly: the HELICAL project dealt with linking electronic health records across populations rather than with molecular cell biology. This trajectory — from bench-science bioinformatics toward clinical data infrastructure — suggests that their underlying competency in managing and integrating complex biological datasets is stable, but the application domain has broadened from research genomics toward real-world health data.

Eagle Genomics appears to be moving from molecular genomics tooling toward clinical data integration, which positions them for future consortia at the intersection of genomics and population health data.

How they like to work

Eagle Genomics participated exclusively as a third party in both H2020 projects, providing infrastructure or hosting researchers without holding a formal consortium seat and without coordinating any project. This pattern suggests they function as a specialist service provider — low overhead for the consortium, but also limited stake in the project's direction. For prospective partners, this means Eagle Genomics is likely easy to bring into a project but will not drive the agenda.

Eagle Genomics has indirect exposure to 40 consortium partners across 13 countries through the MSCA training networks they supported. These figures reflect the full ITN consortia rather than Eagle Genomics' own direct partnership history, so their personal network is likely more concentrated around Cambridge and the UK life sciences corridor.

What sets them apart

Eagle Genomics is a small private company that combines computational genomics with clinical health data work, based inside Cambridge's dense life sciences ecosystem. Unlike academic bioinformatics groups, they operate as a commercial entity — which typically means more reliable delivery timelines and product-grade tooling. For consortia needing a technically credible, non-academic bioinformatics partner from the UK, particularly in immunology or clinical data integration, they fill a specific and hard-to-replace niche.

Highlights from their portfolio

• ENLIGHT-TEN
  A pan-European MSCA training network linking informatics with T helper cell genomics, where Eagle Genomics contributed bioinformatics infrastructure to a consortium studying the molecular basis of autoimmune diseases.
• HELICAL
  Tackled cross-national electronic health record linkage for clinical benefit — a data infrastructure challenge at the frontier of precision medicine — marking Eagle Genomics' transition toward applied clinical informatics.